XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Note 3 - Cash, Cash Equivalents, and Marketable Securities
3 Months Ended
Mar. 31, 2024
Notes to Financial Statements  
Cash, Cash Equivalents, and Marketable Securities [Text Block]

Note 3. Cash, Cash Equivalents, and Marketable Securities

 

Available-for-Sale Securities

 

Available-for-sale securities as of March 31, 2024 were as follows:

 

  

March 31, 2024

 

(in thousands)

 

Amortized Cost

  

Gross Unrealized Gains

  

Gross Unrealized Losses

  

Fair Value

 

Cash equivalents (contractual maturity within 90 days):

                

U.S. Treasury securities

 $12,192  $  $(1) $12,191 

Money market funds

  5,660         5,660 

Total cash equivalents

  17,852      (1)  17,851 

Cash

  3,881         3,881 

Total cash and cash equivalents

 $21,733  $  $(1) $21,732 
                 

Marketable securities (contractual maturity greater than 90 days but less than 1 year):

                

U.S. Treasury securities

 $6,179  $  $(1) $6,178 

Total marketable securities

 $6,179  $  $(1) $6,178 

 

Available-for-sale securities as of  December 31, 2023 were as follows:

 

  

December 31, 2023

 

(in thousands)

 

Amortized Cost

  

Gross Unrealized Gains

  

Gross Unrealized Losses

  

Fair Value

 

Cash equivalents (contractual maturity within 90 days):

                

U.S. Treasury securities

 $19,883  $1  $  $19,884 

Money market funds

  5,113         5,113 

Total cash equivalents

  24,996   1      24,997 

Cash

  3,824         3,824 

Total cash and cash equivalents

 $28,820  $1  $  $28,821 
                 

Marketable securities (contractual maturity greater than 90 days but less than 1 year):

                

U.S. Treasury securities

 $6,179  $  $  $6,179 

Total marketable securities

 $6,179  $  $  $6,179 

 

We received proceeds of $6.3 million and $5.0 million from the maturity of marketable securities during the three months ended March 31, 2024 and 2023, respectively. We had no realized gains or losses from the sale of available-for-sale securities during the three months ended March 31, 2024 and 2023. As of March 31, 2024 and December 31, 2023, we did not have any allowance for credit losses or impairments of available-for-sale securities.